secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2023-09-07T23:59:59+00:00
Accession:  0000950170-23-047058
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani reports 90% success in preclinical RaniPill HC studies; Phase 1 of adalimumab planned
--------------------------------------------------------------------------------

- RaniPill HC delivered teriparatide in 18/20 administrations across two canine studies, a 90% cumulative success rate.
- Payload increased to up to 20 mg, enabling oral delivery of 90+ additional drug candidates.
- Fe57 study showed drug absorption comparable to subcutaneous injection.
- Next milestone: initiate Phase 1 trial of RT-105 (adalimumab) using RaniPill HC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023047058/0000950170-23-047058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023047058/rani-20230907.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-047058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer